Johnson & Johnson shares fall 6.8% on profit and litigation concerns
In short
Johnson & Johnson shares fell as much as 6.8% after its quarterly profit dropped and MedTech came in weaker than expected.
The company still raised its full-year outlook, and revenue plus adjusted earnings beat estimates. The report does not say how big the litigation costs are or how long the stock pressure may last.
What the reporting says
Johnson & Johnson shares fell as much as 6.8% despite an improved full-year earnings outlook. The decline was driven by a sharp drop in reported quarterly profit, weaker-than-expected MedTech performance and litigation-related charges, even as revenue grew and adjusted earnings beat estimates. The immediate consequence is a sharp share-price selloff, while the longer-term legal and operating impact is not stated.
Why it matters
Johnson & Johnson’s stock dropped as much as 6.8% after reported quarterly profit fell, MedTech underperformed and litigation charges weighed on sentiment. The company still had revenue growth, beat adjusted earnings estimates and improved its full-year outlook. That combination suggests investors focused more on near-term profit pressure and legal costs than on the stronger guidance, but the exact litigation exposure is not stated.